Hypothesis

Age‑related methylation of nucleosome‑positioning genes increases chromatin compaction, protecting specific DNA fragments from enzymatic trimming and thereby shifting cfDNA size distributions toward longer fragments.

Mechanistic Basis

Recent work identified ~2,000 age‑differentially methylated CpG sites enriched in nucleosome structure genes [1]. Methylation at CpG islands within promoters of histone chaperones (e.g., NASP, CAF1) and linker histone variants can reduce their expression, leading to tighter nucleosome packing and reduced accessibility of DNA to apoptosis‑associated nucleases. Tighter nucleosomes generate longer protected fragments during apoptosis because the nuclease cuts less frequently between closely spaced nucleosomes. Consequently, plasma from older individuals shows a relative increase of 300‑400 bp cfDNA fragments alongside the canonical ~166 bp peak [2]. This provides a direct mechanistic link between the methylation signature used in cfDNA clocks and the fragmentomics shift observed with age.

Testable Predictions

1. Plasma from individuals with accelerated epigenetic age (e.g., AA>5 years) will have a higher proportion of long cfDNA fragments (>300 bp) after adjusting for total cfDNA concentration.
2. In vitro knockdown of a methylated nucleosome gene (e.g., NASP) in cultured senescent fibroblasts will decrease cfDNA fragment length in the supernatant, shifting the profile toward the mononucleosomal peak.
3. Pharmacological inhibition of DNA methyltransferases (5‑aza‑2′‑deoxycytidine) in aged mice will reduce methylation at nucleosome gene promoters, increase nucleosome gene expression, and normalize the cfDNA fragment size distribution toward that of young mice.
4. Integrating fragment length ratios (long : short) with the 48‑CpG methylation clock will improve prediction of biological age beyond either metric alone (increase in r by ≥0.02, decrease in MAE by ≥0.5 years).

Experimental Design

• Human cohort: Collect plasma from 120 participants stratified by epigenetic age acceleration (low, medium, high). Perform EM‑seq for the 48‑CpG clock and low‑pass cfDNA fragmentomics (size, end‑motif). Use linear models to test association between AA and long‑fragment proportion, controlling for age, sex, and leukocyte count.
• Cell‑culture model: Induce senescence in IMR‑90 fibroblasts via irradiation. Transfect with siRNA against NASP or CAF1. Harvest supernatant after 48 h, quantify cfDNA concentration and fragment size via Bioanalyzer. Compare to scrambled control.
• Mouse intervention: Treat 20‑month‑old C57BL/6 mice with 5‑aza‑dC (0.5 mg/kg, i.p., twice weekly for 4 weeks) or vehicle. At endpoint, isolate plasma, perform EM‑seq for a mouse‑adapted nucleosome‑gene methylation panel, and fragment analysis. Assess changes in nucleosome‑gene expression in liver and spleen by qPCR.
• Integration analysis: Build combined models using elastic net regression with predictors: 48‑CpG methylation score, long‑fragment ratio, short‑fragment ratio, and end‑motif enrichment (e.g., CCCTT). Evaluate performance via 10‑fold cross‑validation.

Potential Impact

Confirming that nucleosome‑gene methylation directly shapes cfDNA fragment lengths would unify two major hallmarks of cfDNA aging—epigenetic alteration and fragmentomic shift—into a single mechanistic framework. It would also provide a actionable target: modulating nucleosome stability could potentially reset cfDNA signatures of aging, offering a novel avenue for biomarker‑guided interventions.